Company Description
Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market, as well as for application in its biothreat, industrial, and partner markets. The company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company’s systems integrate these steps and analyze complex biological samples in its proprietary test cartridges.
Faizan's take
CPHD traded at $31.13 a share on Monday's close. Its chart is showing a perfectly formed head and shoulder topping pattern. Shorting CPHD today might yield a good profit in the near mid term.
Suggested price target $28.55 (8.3% gain).
NOTE: Suggested price targets are very flexible and may change as the price action unfolds. Targets are only suggested to give readers a rough estimate of what to expect from the stock and they should not be used by investors as absolute sell points.
